.Pharmacolibrary.Drugs.ATC.L.L01XK02

Information

Niraparib is an oral, selective poly(ADP-ribose) polymerase (PARP) inhibitor, primarily used as an anti-cancer agent for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is an approved drug for these indications.

Pharmacokinetics

Pharmacokinetic data from adult female ovarian cancer patients after oral administration of niraparib.

References

1. Russu, A, et al., & Boulton, M (2025). Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer. Advances in therapy 42(4) 1860–1880. DOI:10.1007/s12325-025-03104-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/40016438

2. Rubinstein, MM, et al., & Makker, V (2021). A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecologic oncology 160(1) 71–76. DOI:10.1016/j.ygyno.2020.10.019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33139041

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)